Christopher Viehbacher
Known title: President and CEOCIK: 0001774478
Christopher Viehbacher's purchase track record
Christopher Viehbacher has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2026 | BRVE | $1.50M | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BRVE | ▲ Buy | Open Market | 83,333 | $1.5M | 8/7/2026 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 9,008 | $0 | 2/6/2026 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 4,356 | $876K | 2/6/2026 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 15,453 | $0 | 2/6/2026 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 6,624 | $1.3M | 2/6/2026 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 7,040 | $0 | 12/1/2025 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 3,404 | $605K | 12/1/2025 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 9,008 | $0 | 2/7/2025 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 3,201 | $452K | 2/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade
Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.